Skip to main content
DMRA
NASDAQ Life Sciences

Damora Posts $32M Q3 Loss as R&D Spending Jumps; Cash Runs to 2H 2029

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.94
Mkt Cap
$1.416B
52W Low
$4.95
52W High
$38.325
52W Position info
363% above low
Off High info
40% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DMRA has more than doubled off its 52-week low of $4.95.

Summary

Damora's Q3 net loss widened to $32.0 million from $3.1 million a year earlier as R&D jumped to $25.5 million from $1.4 million and G&A rose to $11.4 million from $1.7 million — the company is now spending like a clinical-stage biotech rather than a shell. The balance sheet is the story: $528.5 million in cash and securities as of September 30, with management guiding that funds operations into the second half of 2029, so there is no near-term financing overhang despite the burn. Operationally, the FDA cleared the DMR-001 IND and CLARITY-101 Phase 1/1b enrollment is running at multiple sites, with two proof-of-concept readouts targeted from mid-2027; two DMR-001 abstracts were accepted for ASH in December, including preclinical data claiming an average 95-fold potency edge over a reference antibody across 10 non-Type 1 CALR mutations. The company also signed an exclusive worldwide license with Paragon Therapeutics covering DMR-001 and DMR-002. Next hard catalysts: ASH data in December and the first DMR-002 regulatory submission in Q4 2026.

At the time of this announcement, DMRA was trading at $22.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.95 to $38.33. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DMRA - Latest Insights

DMRA
Nov 04, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $22.94 info
Change: $0 (0%) info
Market Cap: $1.416B info
DMRA
Aug 10, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.54
Real-time Price: $22.94 info
Change: -$6.60 (-22%) info
Market Cap: $1.416B info
DMRA
Aug 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.02
Real-time Price: $22.94 info
Change: -$7.08 (-24%) info
Market Cap: $1.416B info
DMRA
May 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $22.94 info
Change: -$0.120 (-0.52%) info
Market Cap: $1.416B info
DMRA
May 04, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.98
Real-time Price: $22.94 info
Change: -$3.04 (-12%) info
Market Cap: $1.416B info